NDC 50242-0005-01: Enspryng Satralizumab 180 mg/1.5mL Injection, Solution, 1.5 mL Syringe
This is a package of 1 syringe of Enspryng Satralizumab 180 mg/1.5mL Injection, Solution from Genentech, Inc., first listed with the FDA Oct 2026 and currently FDA-listed. It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 50242-005-01 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 50242 labeler · 005 product · 01 package
- Package marketed since
- Oct 15, 2026
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 5024200501 2
- FDA record last changed
- Nov 12, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
- RxCUI (RxNorm): 2391555
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Interleukin inhibitors class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Satralizumab — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 50242-0005-01 You're viewing this Main listing | 1 SYRINGE, PLASTIC in 1 CARTON / 1.5 mL in 1 SYRINGE, PLASTIC | 2026-10-15 | — | Active |
| 50242-0005-86 50242-005-86 | 1 SYRINGE, PLASTIC in 1 CARTON / 1.5 mL in 1 SYRINGE, PLASTIC Sample | 2026-10-15 | — | Active |
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 50242-0005-86?
What NDC number is used to bill for this package of Enspryng Satralizumab 180 mg/1.5mL Injection, Solution?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Enspryng 180 mg/1.5mLthis 50242-0005-01 | Genentech, | 1 syringe | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Purple Book · refreshed Nov 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Why the date isn’t exact: Biosimilar timing can change because patents may be challenged, settled, licensed, added or removed, and litigation can move the real date earlier or later.
🛈 What do these terms mean?
- Biologic patent
- A patent the reference product’s maker has publicly listed. A biosimilar generally can’t launch until these expire — unless they’re invalidated or resolved in a settlement.
- Reference-product exclusivity
- A flat 12 years of FDA market protection from the biologic’s first licensure (the BPCIA). No biosimilar can be licensed before it ends, regardless of patents.
- Interchangeable exclusivity
- The first interchangeable biosimilar can earn a period as the only interchangeable version (pharmacists can substitute it without the prescriber).
- Earliest biosimilar (LOE)
- The latest of all the dates above — the soonest a biosimilar can realistically reach the market. Litigation and settlements can move it earlier.
Biologics have no small-molecule “generics” — competition comes from FDA-licensed biosimilars, tracked in the FDA Purple Book.
| Code | What it grants | Expires |
|---|---|---|
| RefProduct | Reference-product exclusivity (12-year, BPCIA) — no biosimilar can be licensed before this date | Aug 14, 2032 |
Is there a biosimilar for this drug?
Why do different websites show different biosimilar dates?
Can a biosimilar launch before the last patent expires?
What does “current Purple Book estimate” mean?
What does “FDA listed” mean?
What does a patent or protection date mean here?
Where does this data come from?
- FDA Purple Book · refreshed Nov 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 94ZLA3W45F
Arginine is an amino acid used in medicines as a buffer and pH adjuster. It helps maintain the proper acidity level and stability of liquid formulations.
-
UNII 30KYC7MIAI
Aspartic acid is an amino acid used in pharmaceutical formulations as a pH buffer and to help stabilize active ingredients. It works to maintain the proper acidity level in the medicine.
-
UNII 4QD397987E
An amino acid used as a buffer and stabilizer in medications. It helps maintain the pH balance and protects the active drug from breaking down during storage and use.
-
UNII LQA7B6G8JG
A synthetic polymer made by combining water-soluble compounds. It acts as a surfactant and solubilizer to help mix oil and water-based ingredients, improving the medicine's texture and how active ingredients dissolve.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
5 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Genentech, Inc. labeler code 50242
- Enspryng Satralizumab 120 mg/mL Injection, Solution NDC 50242-007-01
- TNKase tenecteplase Kit NDC 50242-014-03
- XOLAIR omalizumab 150 mg/1.2mL Injection, Solution NDC 50242-040-62
- Cathflo Activase Alteplase 2.2 mg/2mL Injection, Powder, Lyophilized, For Solution NDC 50242-041-10
- Activase Alteplase Kit NDC 50242-044-13
- Rituxan rituximab 10 mg/mL Injection, Solution NDC 50242-051-10
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for: the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.1 ) the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients. ( 1.2 )
1.1Neuromyelitis Optica Spectrum Disorder (NMOSD) ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
1.2Thyroid Eye Disease (TED) ENSPRYNG is indicated for the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients.
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION Hepatitis B virus, tuberculosis, and liver transaminase screening is required before the first dose. ( 2.1 ) Prior to every use, determine if there is an active infection. ( 2.2 ) The recommended loading dosage of ENSPRYNG is: NMOSD: for the first three administrations is 120 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 120 mg every 4 weeks.
( 2.2.1 ) TED: for body weight 40-100kg; for the first three administrations is 120 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 120 mg every 4 weeks. For body weight >100 kg: for the first three administrations is 180 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 180 mg every 4 weeks (2.2.2) See Full Prescribing Information for important preparation and administration instructions. ( 2.3 )
2.1Assessments Prior to the First Dose of ENSPRYNG Hepatitis B Virus Screening Prior to initiating ENSPRYNG, perform Hepatitis B virus (HBV) screening. ENSPRYNG is contraindicated in patients with active HBV confirmed by positive results for surface antigen [HBsAg] and anti-HBV tests. For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment with ENSPRYNG [see Contraindications (4) and Warnings and Precautions (5.1) ] .
Tuberculosis Screening Prior to initiating ENSPRYNG, evaluate for active tuberculosis and test for latent infection. For patients with active tuberculosis or positive tuberculosis screening without a history of appropriate treatment, consult infectious disease experts before initiating treatment with ENSPRYNG [see Contraindications (4) and Warnings and Precautions (5.1) ] . Liver Transaminase Screening Liver transaminases and serum bilirubin should be assessed prior to initiation of treatment with ENSPRYNG [see Warnings and Precautions (5.2) ] .
Caution should be exercised when considering initiation of ENSPRYNG treatment in patients whose aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels are greater than 1.5 times the upper limit of normal (ULN). Vaccinations Because vaccination with live-attenuated or live vaccines is not recommended during treatment with ENSPRYNG, administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of ENSPRYNG for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of ENSPRYNG for non-live vaccines [see Warnings and Precautions (5.1) ].
2.2Recommended Dosage For subcutaneous use only. Prior to every use of ENSPRYNG, advise patients to consult with their healthcare professional (HCP) if they suspect an active infection, including localized infections. In case of active infection, delay use of ENSPRYNG until the infection is resolved [see Warnings and Precautions (5.1) ] .
Recommended Dosage for NMOSD The recommended loading dosage of ENSPRYNG for the first three administrations is 120 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 120 mg every 4 weeks. Recommended Dosage for TED The recommended dose is based on the patient's body weight, as shown in Table 1 . Table 1 ENSPRYNG Dosing Regimen Based on Body Weight for TED Body Weight Dosing is based on actual body weight.
40 kg to less than or equal to 100 kg Greater than 100 kg ** "0 weeks" refers to time of the first administration. Loading Dose Every 2 weeks for the first three administrations. Weeks 0 , 2 and 4 120 mg 180 mg Maintenance Dose From week 8 and every 4 weeks thereafter 120 mg 180 mg The safety and effectiveness of ENSPRYNG have not been established in TED patients weighing less than 40 kg.
Missed Dose If a dose of ENSPRYNG is missed for any reason other than increases in liver enzymes [see Dosage and Administration (2.4) ] , administer as described in Table 2 . Table 2 Recomme… [Excerpted — this section continues on DailyMed.]
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS ENSPRYNG is a clear, and colorless to slightly yellow solution available as: Injection: 120 mg/mL in single-dose prefilled syringe. Injection: 120 mg/mL in single-dose autoinjector. Injection: 180 mg/1.5 mL in single-dose autoinjector Injection: 120 mg/mL in a single-dose prefilled syringe ( 3 ) Injection: 120 mg/mL in a single-dose prefilled autoinjector ( 3 ) Injection: 180 mg/1.5 mL in a single-dose prefilled autoinjector ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS ENSPRYNG is contraindicated in patients with: A known hypersensitivity to satralizumab or any of the inactive ingredients [see Warnings and Precautions (5.4) ] Active Hepatitis B infection [see Warnings and Precautions (5.1) ] Active or untreated latent tuberculosis [see Warnings and Precautions (5.1) ] Known hypersensitivity to satralizumab or any of the inactive ingredients ( 4 ) Active Hepatitis B infection ( 4 ) Active or untreated latent tuberculosis ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Infections: Delay ENSPRYNG administration in patients with an active infection until the infection is resolved. Vaccination with live or live-attenuated vaccines is not recommended during treatment. ( 5.1 ) Elevated Liver Enzymes: Monitor ALT and AST levels during treatment; interruption of ENSPRYNG may be required. ( 5.2 ) Decreased Neutrophil Counts: Monitor neutrophils during treatment. ( 5.3 )
5.1Infections An increased risk of infections, including serious and potentially fatal infections, has been observed in patients treated with IL-6 receptor antagonists, including ENSPRYNG. The most common infections reported in a randomized clinical trial of patients treated with ENSPRYNG who were not on other chronic immunosuppressant therapies (Study 1), and that occurred more often than in patients receiving placebo, were nasopharyngitis (12%) and cellulitis (10%). The most common infections in patients who were on an additional concurrent immunosuppressant, and that occurred more often than in patients receiving placebo, were nasopharyngitis (31%), upper respiratory infection (19%), and pharyngitis (12%).
Delay ENSPRYNG administration in patients with an active infection, including localized infections, until the infection is resolved. Hepatitis B Virus (HBV) Reactivation Risk of HBV reactivation has been observed with other immunosuppressant therapies. Patients with chronic HBV infection were excluded from clinical trials.
Perform HBV screening in all patients before initiation of treatment with ENSPRYNG. Do not administer ENSPRYNG to patients with active hepatitis. For patients who are chronic carriers of HBV [HBsAg+] or are negative for HBsAg and positive for HB core antibody [HBcAb+], consult liver disease experts before starting and during treatment with ENSPRYNG.
Tuberculosis Tuberculosis has occurred in patients treated with other interleukin-6 receptor antagonists. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating ENSPRYNG. Consider anti-tuberculosis therapy prior to initiation of ENSPRYNG in patients with a history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.
Consult infectious disease experts regarding whether initiating anti-tuberculosis therapy is appropriate before starting treatment. Patients should be monitored for the development of symptoms and signs of tuberculosis with ENSPRYNG, even if initial tuberculosis testing is negative. Vaccinations Live or live-attenuated vaccines should not be given concurrently with ENSPRYNG because clinical safety has not been established.
Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of ENSPRYNG for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of ENSPRYNG for non-live vaccines.
5.2Elevated Liver Enzymes Mild and moderate elevations of liver enzymes have been observed in patients treated with ENSPRYNG at a higher incidence than in patients receiving placebo [see Adverse Reactions (6.1) ] . ALT and AST levels should be monitored every 4 weeks for the first 3 months of treatment, followed by every 3 months for one year, and thereafter, as clinically indicated [see Dosage and Administration (2.4) ].
5.3Decreased Neutrophil Counts Decreases in neutrophil counts were observed in patients treated with ENSPRYNG at a higher incidence than placebo [see Adverse Reactions (6.1) ]. Neutrophil counts should be monitored 4 to 8 weeks after initiation of therapy, and thereafter at regular clinically determined intervals [see Dosage and Administration (2.4) ].
5.4Hypersensitivity Reactions Hypersensitivity reactions, including rash, urticaria, and fatal anaphylaxis, have occurred with other interleukin-6 receptor antagonists.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Infections [see Warnings and Precautions (5.1) ] Elevated Liver Enzymes [see Warnings and Precautions (5.2) ] Decreased Neutrophil Counts [see Warnings and Precautions (5.3) ] Hypersensitivity Reactions [see Warnings and Precautions (5.4) ] The most common adverse reactions in patients with NMOSD (incidence at least 15%) are nasopharyngitis, headache, upper respiratory tract infection, gastritis, rash, arthralgia, extremity pain, fatigue, and nausea.
( 6.1 ) The most common adverse reactions in patients with TED (incidence at least 5%) are upper respiratory tract infection, and alanine aminotransferase increased. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice. Adverse Reactions Neuromyelitis Optica Spectrum Disorder (NMOSD) The safety of ENSPRYNG in NMOSD was evaluated in two randomized, placebo-controlled clinical trials [Study 1 evaluated ENSPRYNG without concurrent immunosuppressive therapy (IST) and Study 2 evaluated ENSPRYNG with concurrent IST], which included 41 anti-AQP4 seropositive patients treated with ENSPRYNG in Study 1 and 26 anti-AQP4 seropositive patients treated with ENSPRYNG in Study 2 [see Clinical Studies (14) ] .
In the double-blind, controlled period, the median exposure time on ENSPRYNG treatment was approximately 2 years in Study 1 and approximately 3 years in Study 2. The median exposure time on placebo treatment was approximately 1 year in both Study 1 and Study 2. Adverse reactions that occurred in Study 1 and Study 2 in more than 5% of patients treated with ENSPRYNG, and at a greater incidence than in patients who received placebo, are shown in Table 4 and Table 5 .
The most common adverse reactions (15% or greater with ENSPRYNG in either) were nasopharyngitis, headache, upper respiratory tract infection, gastritis, rash, arthralgia, extremity pain, fatigue, and nausea. Table 4 Adverse Reactions Occurring in 4 or More Patients Treated with ENSPRYNG and Greater Incidence than Placebo in Patients with NMOSD in Study 1 Adverse Reaction ENSPRYNG (N = 41) % PLACEBO (N = 23) % Rash 17 0 Arthralgia 17 0 Pain in extremity 15 9 Fatigue 15 4 Nausea 15 9 Nasopharyngitis 12 4 Pruritus 10 0 Depression 10 0 Cellulitis 10 0 Neutropenia 10 4 Blood creatine phosphokinase increased 10 4 Fall 10 4 Table 5 Adverse Reactions Occurring in 3 or More Patients Treated with ENSPRYNG and Greater Incidence than Placebo in Patients with NMOSD in Study 2 Adverse Reaction ENSPRYNG + IST (N = 26) % PLACEBO + IST (N = 26) % Nasopharyngitis 31 15 Headache 27 12 Upper respiratory tract infection 19 12 Gastritis 15 0 Arthralgia 12 0 Pharyngitis 12 8 Thyroid Eye Disease (TED) The safety of ENSPRYNG in TED was evaluated in two phase III randomized, double-masked, placebo-controlled, multicenter clinical trials (Study 3 and Study 4) which included 131 patients treated with ENSPRYNG.
Adverse reactions that occurred in Study 3 and Study 4 in more than 5% of patients treated with ENSPRYNG, and at a greater incidence than in patients who received placebo, are shown in Table 6 . Table 6 Adverse Reactions Occurring in 5% or More of Patients Treated with ENSPRYNG and Greater Incidence than Placebo in Patients with TED (Study 3 and Study 4 Pooled Analysis) Adverse Reaction ENSPRYNG (N = 131) % PLACEBO (N = 124) % Upper respiratory tract infection 5.3
2.4Alanine aminotransferase increased 5.3
0.8Neutropenia was also reported with less than 5% occurrence. Injection-Related Reactions NMOSD In Study 1 and Study 2, injection-related reactions were re… [Excerpted — this section continues on DailyMed.]
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women with NMOSD exposed to ENSPRYNG during pregnancy. Healthcare providers are encouraged to register NMOSD patients and pregnant women with NMOSD are encouraged to register themselves by calling 1-833-277-9338. Risk Summary There are no adequate data on the developmental risk associated with the use of ENSPRYNG in pregnant women.
In an animal reproduction study, no adverse effects on maternal animals or fetal development were observed in pregnant monkeys and their offspring, with administration of satralizumab-mwge at doses up to 50 mg/kg/week (see Data ) . In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2 – 4% and 15 – 20%, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
ENSPRYNG should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Clinical Considerations Fetal/neonatal adverse reactions Monoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to infants exposed to ENSPRYNG in utero [see Warnings and Precautions (5.1) ] .
Data Animal Data Weekly subcutaneous administration of satralizumab-mwge (0, 2, or 50 mg/kg) to monkeys throughout pregnancy resulted in no adverse effects on postnatal development of the offspring; however, immune function was impaired in offspring at both doses. Plasma exposures (C ave ) in dams at the low and high doses were approximately 3 and 100 times, respectively, that in humans at the recommended monthly maintenance dose of 120 mg.
8.2Lactation Risk Summary No information is available on the presence of satralizumab-mwge in human milk, the effects of the satralizumab-mwge on the breastfed infant, or the effects of the satralizumab-mwge on milk production. Satralizumab-mwge was excreted in the milk of lactating monkeys administered satralizumab-mwge throughout pregnancy. Human IgG is excreted in human milk and the potential for absorption in the infant is unknown.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ENSPRYNG and any potential adverse effects on the breastfed infant from ENSPRYNG or from the underlying maternal condition.
8.4Pediatric Use Safety and effectiveness in pediatric patients have not been established.
8.5Geriatric Use Clinical studies of ENSPRYNG did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. However, population pharmacokinetic analyses in patients with NMOSD and TED did not show that age affected the pharmacokinetics of satralizumab-mwge [see Clinical Pharmacology (12.3) ] . In general, caution should be used when dosing the elderly, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.
🤰 Pregnancy ▾
8.1Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women with NMOSD exposed to ENSPRYNG during pregnancy. Healthcare providers are encouraged to register NMOSD patients and pregnant women with NMOSD are encouraged to register themselves by calling 1-833-277-9338. Risk Summary There are no adequate data on the developmental risk associated with the use of ENSPRYNG in pregnant women.
In an animal reproduction study, no adverse effects on maternal animals or fetal development were observed in pregnant monkeys and their offspring, with administration of satralizumab-mwge at doses up to 50 mg/kg/week (see Data ) . In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2 – 4% and 15 – 20%, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
ENSPRYNG should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Clinical Considerations Fetal/neonatal adverse reactions Monoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to infants exposed to ENSPRYNG in utero [see Warnings and Precautions (5.1) ] .
Data Animal Data Weekly subcutaneous administration of satralizumab-mwge (0, 2, or 50 mg/kg) to monkeys throughout pregnancy resulted in no adverse effects on postnatal development of the offspring; however, immune function was impaired in offspring at both doses. Plasma exposures (C ave ) in dams at the low and high doses were approximately 3 and 100 times, respectively, that in humans at the recommended monthly maintenance dose of 120 mg.
🧒 Pediatric Use ▾
8.4Pediatric Use Safety and effectiveness in pediatric patients have not been established.
🧓 Geriatric Use ▾
8.5Geriatric Use Clinical studies of ENSPRYNG did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. However, population pharmacokinetic analyses in patients with NMOSD and TED did not show that age affected the pharmacokinetics of satralizumab-mwge [see Clinical Pharmacology (12.3) ] . In general, caution should be used when dosing the elderly, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action The precise mechanism by which satralizumab-mwge exerts therapeutic effects in NMOSD and TED is unknown but is presumed to involve inhibition of IL-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors.
12.2Pharmacodynamics The relationship between any of the pharmacodynamic effects of ENSPRYNG and clinical outcomes in NMOSD and TED is unknown.
12.3Pharmacokinetics The pharmacokinetics of ENSPRYNG have been characterized in healthy volunteers, and in NMOSD and TED patients. Population pharmacokinetic analyses were performed on databases of 154 NMOSD patients and 131 TED patients. ENSPRYNG's pharmacokinetics was best described by a two-compartment population pharmacokinetic model with parallel linear and target-mediated (Michaelis-Menten) elimination and first-order SC absorption.
ENSPRYNG clearance and volume parameters allometrically scaled by body weight (through power function with the fixed power coefficient of 0.75 and 1 for clearance and volume parameters, respectively) The pharmacokinetics of satralizumab-mwge following administration of ENSPRYNG by prefilled syringe or autoinjector were comparable. In patients with NMOSD using the recommended dose, steady state pharmacokinetics were achieved after the loading period (8 weeks) as follows [mean (±SD)]: C min : 19.7 (12.2) mcg/mL, C max : 31.5 (14.9) mcg/mL, and AUC: 737 (386) mcg.day/mL.
In patients with TED using the recommended dose, steady state pharmacokinetics were achieved after the loading period (8 weeks) as follows (mean (±SD)): C min : 17.7 (9.64) mcg/mL, C max : 28.7 (11.3) mcg/mL and AUC: 666 (301) mcg.day/mL. Absorption The median time to maximum concentration (T max ) at steady state was approximately 6 days based on population pharmacokinetic analyses. The bioavailability of satralizumab-mwge was 85%.
In healthy subjects, the bioavailability of satralizumab was comparable following a single subcutaneous injection with the auto-injector and the prefilled syringes. Distribution Satralizumab-mwge undergoes biphasic distribution. The central volume of distribution was
3.46 L and the peripheral volume of distribution was
2.07L. The inter-compartmental clearance was 0.336 L/day. Elimination The total clearance of satralizumab-mwge is concentration-dependent.
Linear clearance (accounting for approximately half of the total clearance at steady state using the recommended dose) is estimated to be 0.0601 L/day. The associated terminal t 1/2 is approximately 30 days based on data pooled from all studies. Metabolism The metabolism of satralizumab-mwge has not been directly studied, as antibodies are cleared principally by catabolism.
Excretion Monoclonal antibodies, including satralizumab-mwge, are not eliminated via renal or hepatic pathways. Specific Populations Population pharmacokinetic analyses in patients with NMOSD or with TED showed that age, gender, and race did not meaningfully influence the pharmacokinetics of satralizumab-mwge. Patients with Renal or Hepatic Impairment No formal studies of the effect of renal impairment or hepatic impairment on the pharmacokinetics of satralizumab-mwge were conducted.
Drug Interaction Studies No formal drug-drug interaction studies have been performed with ENSPRYNG. Based on population pharmacokinetic analyses of the available data, the impact of commonly used small molecule drugs on the pharmacokinetics of satralizumab-mwge remains inconclusive. Suppression of IL-6 signaling by treatment with ENSPRYNG, from the low baseline levels seen in NMOSD and TED Studies is expected to have a minor impact on exposure of concomitant medications metabolized by CYP450 enzymes.
The clinical significance of this is unknown.
🧬 Mechanism of Action ▾
12.1Mechanism of Action The precise mechanism by which satralizumab-mwge exerts therapeutic effects in NMOSD and TED is unknown but is presumed to involve inhibition of IL-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1How Supplied ENSPRYNG (satralizumab-mwge) injection is available as a sterile, preservative-free, clear, colorless to slightly yellow solution for subcutaneous injection in a single-dose prefilled syringe (PFS) with needle safety device or a single-dose autoinjector. ENSPRYNG prefilled syringe and autoinjector are not made with natural rubber latex. Each ENSPRYNG carton contains either: One single-dose 120 mg/mL prefilled syringe (NDC 50242‑007‑01) One single-dose 120 mg/mL autoinjector (NDC 50242-007-55).
One single-dose 180 mg/1.5mL autoinjector (NDC 50242-005-01).
16.2Storage and Handling Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake. ENSPRYNG can be stored out of refrigeration for a maximum of 8 days at a temperature that does not exceed 30°C (86°F). If ENSPRYNG is removed from and returned to the refrigerator, the total combined time out of refrigeration should not exceed 8 days. Always keep in the original carton to protect from light.
📦 Storage and Handling ▾
16.2Storage and Handling Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake. ENSPRYNG can be stored out of refrigeration for a maximum of 8 days at a temperature that does not exceed 30°C (86°F). If ENSPRYNG is removed from and returned to the refrigerator, the total combined time out of refrigeration should not exceed 8 days. Always keep in the original carton to protect from light.
📋 Description ▾
11 DESCRIPTION Satralizumab-mwge is a recombinant humanized anti-human interleukin 6 (IL-6) receptor monoclonal antibody based on a human IgG2 framework. Each light chain and heavy chain consists of 214 and 443 amino acids, respectively. Satralizumab-mwge is a glycoprotein with an approximate molecular weight of 143 kDa and is produced by recombinant DNA technology in Chinese hamster ovary cells.
The binding of satralizumab-mwge to the IL-6 receptor is pH-sensitive. ENSPRYNG (satralizumab-mwge) injection for subcutaneous administration is supplied as a sterile, clear, colorless to slightly yellow solution with no preservative, and with an approximate pH of 6. ENSPRYNG is supplied in a single-dose 1 mL prefilled syringe with a needle safety device or a single-dose 1 mL or 1.5 mL autoinjector that contains a prefilled syringe.
Each prefilled syringe delivers 1 mL of solution containing 120 mg satralizumab-mwge, L-arginine (26.1 mg), L-aspartic acid (pH adjustment), L-histidine (3.1 mg), poloxamer 188 (0.5 mg), and Water for Injection, USP. Each prefilled autoinjector delivers either: 1 mL of solution containing 120 mg satralizumab-mwge, L-arginine (26.1 mg), L-aspartic acid (pH adjustment), L-histidine (3.1 mg), poloxamer 188 (0.5 mg), and Water for Injection, USP. 1.5 mL of solution containing 180 mg satralizumab-mwge, L-arginine (39.2 mg), L-aspartic acid (pH adjustment), L-histidine (4.65 mg), poloxamer 188 (0.75 mg), and Water for Injection, USP.
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Advise the patients to read the FDA-approved patient labeling ( Medication Guide and Instructions for Use ). Infections Inform patients that an increased risk of infections, including serious and potentially fatal infections, has been observed in patients treated with IL-6 receptor antagonists, including ENSPRYNG. Instruct patients to contact their healthcare provider immediately when symptoms suggesting infection (e.g., fever, chills, constant cough, or sore throat) appear during treatment [see Warning and Precautions (5.1) ] .
Vaccinations Advise patients to complete any required vaccinations at least 4 weeks prior to initiation of ENSPRYNG for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of ENSPRYNG for non-live vaccines [see Warnings and Precautions 5.1 ]. Elevated Liver Enzymes Inform patients on the importance of liver enzyme testing [see Warnings and Precautions (5.2) ]. Decreased Neutrophil Counts Inform patients on the importance of neutrophil count testing [see Warnings and Precautions (5.3) ].
Hypersensitivity Reactions Inform patients about the signs and symptoms of hypersensitivity reactions and anaphylaxis and advise them to contact their healthcare provider immediately if these symptoms occur [see Warnings and Precautions (5.4) ] . Instruction on Injection Technique Instruct patients and caregivers to read the Instructions for Use before the patient starts using ENSPRYNG, and each time the patient gets a refill as there may be new information they need to know. Perform the first injection under the guidance of a qualified healthcare professional.
If a patient or caregiver is to administer subcutaneous ENSPRYNG, instruct him/her in injection techniques and assess his/her ability to inject subcutaneously to ensure proper administration of subcutaneous ENSPRYNG and the suitability for home use [see Dosage and Administration (2.3) and Instructions for Use ]. Instruct patients to remove the prefilled syringe or autoinjector from the refrigerator prior to use and allow it to sit at room temperature outside of the carton for 30 minutes. Do not warm ENSPRYNG in any other way.
Instruct patients to use the syringe or the autoinjector within 5 minutes of removing the cap. Do not remove the cap until ready to inject. Advise patients not to touch the green needle shield of the autoinjector or put the cap back on after it has been removed, as this may unintentionally activate the autoinjector.
Advise patients to consult their healthcare provider if the full dose is not received. A puncture-resistant container for disposal of syringes should be used and should be kept out of the reach of children. Instruct patients or caregivers in the technique as well as proper prefilled syringe or autoinjector disposal, and caution against reuse of these items.
Pregnancy Exposure Registry for NMOSD Encourage patients to enroll in the ENSPRYNG Pregnancy Registry if they become pregnant while taking ENSPRYNG for NMOSD. The Registry monitors fetal outcomes of pregnant women with NMOSD exposed to ENSPRYNG [see Use in Specific Populations (8.1) ].
💬 Medication Guide ▾
This Medication Guide has been approved by the U.S. Food and Drug Administration Revised: 10/2026 MEDICATION GUIDE ENSPRYNG ® (en-spryng) (satralizumab-mwge) injection, for subcutaneous use What is the most important information I should know about ENSPRYNG? ENSPRYNG may cause serious side effects including: 1.
Infections. ENSPRYNG can increase your risk of serious infections some of which can be life-threatening. Talk to your healthcare provider if you are being treated for an infection or call them right away if you think you have signs of an infection, with or without a fever, such as: chills, feeling tired, muscle aches, cough that will not go away or a sore throat. skin redness, swelling, tenderness, pain or sores on your body. diarrhea, belly pain, or feeling sick. burning when you urinate or urinating more often than usual.
Your healthcare provider will check if you have an infection and treat it if needed before you start or continue to take ENSPRYNG. Your healthcare provider should test you for hepatitis and tuberculosis (TB) before you start taking ENSPRYNG. All required vaccinations should be completed before starting ENSPRYNG.
People using ENSPRYNG should not be given 'live' or 'live-attenuated' vaccines. 'Live' or 'live-attenuated' vaccines should be given at least 4 weeks before you start ENSPRYNG. Your healthcare provider may recommend that you get a 'non-live' (inactivated) vaccine, such as some of the seasonal flu vaccines. If you plan to get a 'non-live' (inactivated) vaccine, it should be given, whenever possible, at least 2 weeks before you start ENSPRYNG.
2. Increased liver enzymes. Your healthcare provider should order blood tests to check your liver enzymes before and while you are taking ENSPRYNG.
Your healthcare provider will tell you how often you will need to have these blood tests. Make sure you get all of your follow-up blood tests as ordered by your healthcare provider. Your healthcare provider will tell you if you need to wait to start ENSPRYNG if your liver enzymes are increased.
3. Low neutrophil count. ENSPRYNG can cause a decrease in your neutrophil counts in your blood.
Neutrophils are white blood cells that help the body fight off bacterial infections. Your healthcare provider should order blood tests to check your neutrophil count while you are taking ENSPRYNG. See " What are the possible side effects with ENSPRYNG? " What is ENSPRYNG?
ENSPRYNG is a prescription medicine used to treat: neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 (AQP4) antibody positive. thyroid eye disease (TED) no matter how severe it is or how long a person has had it. It is not known if ENSPRYNG is safe and effective in children. Do not take ENSPRYNG if you: are allergic to satralizumab-mwge or any of the ingredients in ENSPRYNG.
See " What are the ingredients in ENSPRYNG? " at the end of this Medication Guide for a complete list of ingredients in ENSPRYNG. have an active hepatitis B infection. have active or untreated inactive (latent) TB. Before you take ENSPRYNG, tell your healthcare provider about all of your medical conditions, including if you: have or think you have an infection. See " What is the most important information I should know about ENSPRYNG? " have liver problems. have ever had hepatitis B or are a carrier of the hepatitis B virus.. have had or have been in contact with someone with tuberculosis. have had a recent vaccination or are scheduled to receive any vaccination. are pregnant, think that you might be pregnant, or plan to become pregnant.
It is not known if ENSPRYNG will harm your unborn baby. Pregnancy Registry : There is a registry for pregnant women who take ENSPRYNG for NMOSD. The purpose of this registry is to check the health of the pregnant mother and her baby.
If you are pregnant or become pregnant while taking ENSPRYNG for NMOSD, talk to your healthcare provider about how you can join this pregnancy registry, or you may contact the registry at 1-833-277… [Excerpted — this section continues on DailyMed.]
🧬 Pharmacokinetics ▾
12.3Pharmacokinetics The pharmacokinetics of ENSPRYNG have been characterized in healthy volunteers, and in NMOSD and TED patients. Population pharmacokinetic analyses were performed on databases of 154 NMOSD patients and 131 TED patients. ENSPRYNG's pharmacokinetics was best described by a two-compartment population pharmacokinetic model with parallel linear and target-mediated (Michaelis-Menten) elimination and first-order SC absorption.
ENSPRYNG clearance and volume parameters allometrically scaled by body weight (through power function with the fixed power coefficient of 0.75 and 1 for clearance and volume parameters, respectively) The pharmacokinetics of satralizumab-mwge following administration of ENSPRYNG by prefilled syringe or autoinjector were comparable. In patients with NMOSD using the recommended dose, steady state pharmacokinetics were achieved after the loading period (8 weeks) as follows [mean (±SD)]: C min : 19.7 (12.2) mcg/mL, C max : 31.5 (14.9) mcg/mL, and AUC: 737 (386) mcg.day/mL.
In patients with TED using the recommended dose, steady state pharmacokinetics were achieved after the loading period (8 weeks) as follows (mean (±SD)): C min : 17.7 (9.64) mcg/mL, C max : 28.7 (11.3) mcg/mL and AUC: 666 (301) mcg.day/mL. Absorption The median time to maximum concentration (T max ) at steady state was approximately 6 days based on population pharmacokinetic analyses. The bioavailability of satralizumab-mwge was 85%.
In healthy subjects, the bioavailability of satralizumab was comparable following a single subcutaneous injection with the auto-injector and the prefilled syringes. Distribution Satralizumab-mwge undergoes biphasic distribution. The central volume of distribution was
3.46 L and the peripheral volume of distribution was
2.07L. The inter-compartmental clearance was 0.336 L/day. Elimination The total clearance of satralizumab-mwge is concentration-dependent.
Linear clearance (accounting for approximately half of the total clearance at steady state using the recommended dose) is estimated to be 0.0601 L/day. The associated terminal t 1/2 is approximately 30 days based on data pooled from all studies. Metabolism The metabolism of satralizumab-mwge has not been directly studied, as antibodies are cleared principally by catabolism.
Excretion Monoclonal antibodies, including satralizumab-mwge, are not eliminated via renal or hepatic pathways. Specific Populations Population pharmacokinetic analyses in patients with NMOSD or with TED showed that age, gender, and race did not meaningfully influence the pharmacokinetics of satralizumab-mwge. Patients with Renal or Hepatic Impairment No formal studies of the effect of renal impairment or hepatic impairment on the pharmacokinetics of satralizumab-mwge were conducted.
Drug Interaction Studies No formal drug-drug interaction studies have been performed with ENSPRYNG. Based on population pharmacokinetic analyses of the available data, the impact of commonly used small molecule drugs on the pharmacokinetics of satralizumab-mwge remains inconclusive. Suppression of IL-6 signaling by treatment with ENSPRYNG, from the low baseline levels seen in NMOSD and TED Studies is expected to have a minor impact on exposure of concomitant medications metabolized by CYP450 enzymes.
The clinical significance of this is unknown.
🧬 Pharmacodynamics ▾
12.2Pharmacodynamics The relationship between any of the pharmacodynamic effects of ENSPRYNG and clinical outcomes in NMOSD and TED is unknown.
🔬 Clinical Studies ▾
14 CLINICAL STUDIES
14.1Clinical Studies in NMOSD The efficacy of ENSPRYNG for the treatment of NMOSD in adult patients was established in two studies. Study 1 was a randomized (2:1), placebo-controlled trial in 95 patients without concurrent IST (Study 1, NCT02073279) in which 64 patients were anti-AQP4 antibody positive and 31 patients were anti-AQP4 antibody negative. Study 2 was a randomized (1:1), placebo-controlled trial in 76 adult patients with concurrent IST (Study 2, NCT02028884).
Of these, 52 adult patients were anti-AQP4 antibody positive and 24 adult patients were anti-AQP4 antibody negative. Patients met the following eligibility criteria: Study 1: Clinical evidence of 1 relapse in the previous 12 months Study 2: Clinical evidence of at least 2 relapses in the previous 2 years, at least one of which must have occurred in the previous year EDSS score of 0 to 6.5 (both studies) Study 1: Patients were excluded if previously treated with IST within an interval specified for each such therapy Study 2: One of the following baseline treatments at a stable dose as a monotherapy for 8 weeks prior to baseline: azathioprine, mycophenolate mofetil, oral corticosteroids In Study 1, 41 anti-AQP4 antibody positive adult patients were randomized to and received ENSPRYNG and 23 received placebo.
Females accounted for 76% of the ENSPRYNG group and 96% of the placebo group. The remaining baseline demographic characteristics were balanced between the treatment groups. The mean age was 44 years.
Fifty percent were White, 22% were Black or African-American, and 20% were Asian. The mean EDSS score was 3.8. In Study 2, 26 anti-AQP4 antibody positive adult patients were randomized to and received ENSPRYNG and 26 received placebo.
All patients were receiving either concurrent azathioprine (42%), oral corticosteroids (52%), or mycophenolate mofetil (6%) during the trial. The baseline demographic and disease characteristics were balanced between the treatment groups. Females accounted for 100% of the study population.
Forty-six percent of patients were White and 52% were Asian. The mean age was 46 years. The mean EDSS score was 4.0.
All potential relapses were adjudicated by a blinded Clinical Endpoint Committee (CEC). The primary efficacy endpoint for both studies was the time to the first CEC-confirmed relapse. In Study 1, the time to the first CEC-confirmed relapse was significantly longer in ENSPRYNG-treated patients compared to patients who received placebo (risk reduction 55%; hazard ratio 0.45; p = 0.0184).
In the anti-AQP4 antibody positive population, there was a 74% risk reduction; hazard ratio 0.26; p = 0.0014 ( Table 7 ; Figure 1 ). There was no evidence of a benefit in the anti-AQP4 antibody negative patients. In Study 2, the time to the first CEC-confirmed relapse was significantly longer in patients treated with ENSPRYNG compared to patients who received placebo (risk reduction 62%; hazard ratio 0.38; p = 0.0184).
In the anti-AQP4 antibody positive population, there was a 78% risk reduction; hazard ratio 0.22; p = 0.0143 ( Table 7 ; Figure 2 ). There was no evidence of a benefit in the anti-AQP4 antibody negative patients. Table 7 Efficacy Results from Study 1 and Study 2 in anti-AQP4 Antibody Positive NMOSD Patients Study 1 Study 2 ENSPRYNG N=41 Placebo N=23 ENSPRYNG + IST IST = immunosuppressant therapy N= 26 Placebo + IST N=26 Time to Clinical Endpoint Committee (CEC)-Determined Relapse (Primary Efficacy Endpoint) Number (%) of Patients with Relapse 9 (22) 13 (56.5) 3 (11.5) 11 (42.3) Hazard Ratio (95% CI) 0.26 (0.11, 0.63) 0.22 (0.06, 0.82) p-value 0.0014 0.0143 Risk Reduction 74% 78% Proportion of Protocol Defined Relapse-Free Patients at 96 Weeks 76.5% 41.1% 91.1% 56.8% Figure 1 Study 1: Time to First CEC-Determined NMOSD Relapse in the Randomized Controlled Period in the ITT Population Anti-AQP4 Antibody Positive Patients Figure 2 Study 2: Time to First CEC-Determined NMOSD Relapse in the Randomized Controlled Period… [Excerpted — this section continues on DailyMed.]
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Carcinogenicity studies of satralizumab-mwge were not conducted. Mutagenesis Genetic toxicology studies of satralizumab-mwge were not conducted. As an antibody, satralizumab-mwge is not expected to interact directly with DNA.
Impairment of Fertility In monkeys administered satralizumab-mwge (0, 2, 10, or 50 mg/kg) weekly by subcutaneous injection for 26 weeks, no effects on sperm, estrus cycle, or male and female reproductive organs were observed. At the high dose, plasma exposures (C ave ) were approximately 100 times that in humans at the recommended monthly maintenance dose of 120 mg.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Carcinogenicity studies of satralizumab-mwge were not conducted. Mutagenesis Genetic toxicology studies of satralizumab-mwge were not conducted. As an antibody, satralizumab-mwge is not expected to interact directly with DNA.
Impairment of Fertility In monkeys administered satralizumab-mwge (0, 2, 10, or 50 mg/kg) weekly by subcutaneous injection for 26 weeks, no effects on sperm, estrus cycle, or male and female reproductive organs were observed. At the high dose, plasma exposures (C ave ) were approximately 100 times that in humans at the recommended monthly maintenance dose of 120 mg.
📖 Instructions for Use ▾
INSTRUCTIONS FOR USE ENSPRYNG ® (en-spryng) (satralizumab-mwge) Injection, for subcutaneous use single-dose prefilled syringe Read this Instructions for Use before you start using the ENSPRYNG syringe and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
Your healthcare provider will show you or your caregiver how to use the ENSPRYNG syringe the right way. Talk to your healthcare provider if you have any questions. Important information you need to know before injecting ENSPRYNG Do not use the ENSPRYNG prefilled syringe until your healthcare provider has trained you or your caregiver on the right way to inject.
Do not share your ENSPRYNG syringe with other people. You may give them a serious infection or get a serious infection from them. Do not use if the expiration (EXP) date has passed.
Do not use if the seals on the carton have been broken. Do not try to take the syringe apart at any time. Do not take the needle cap off until you are ready to inject ENSPRYNG.
Do not use the syringe if it has been dropped or damaged. Do not re-use the same syringe. Each prefilled syringe can be used only 1 time.
Do not inject through clothing. How should I store the ENSPRYNG prefilled syringe? Store ENSPRYNG in the refrigerator between 36°F to 46°F (2°C to 8°C) in the original carton to protect from light.
Do not freeze. Do not use ENSPRYNG if it has been frozen. Do not shake.
The ENSPRYNG carton can be stored at room temperature up to 86°F (30°C) for up to 8 days. If ENSPRYNG is removed from and returned to the refrigerator the total combined time out of the refrigerator should not be more than 8 days. Always keep in the original carton to protect from light.
Keep ENSPRYNG and all medicines out of the reach of children. Supplies needed to give your injection Each ENSPRYNG carton contains: 1 prefilled syringe for 1-time use only. Not included in the carton: 1 alcohol pad 1 sterile cotton ball or gauze 1 small bandage 1 FDA-cleared, puncture-resistant sharps container for safe disposal of the needle cap and used syringe.
See Step 21 "Disposing of ENSPRYNG" at the end of this Instructions for Use . Always check that you have the right medicine and dose that your healthcare provider prescribed. ENSPRYNG prefilled syringe (See Figure A and Figure B ) Before use: Figure A After use: Figure B The syringe has a needle-shield that automatically covers the needle when the injection is complete.
Prepare to use ENSPRYNG Step 1. Take the carton containing the syringe out of the refrigerator and place it on a clean, flat work surface (like a table). Step 2.
Check the expiration (EXP) date on the back of the carton (See Figure C ) . Do not use if the expiration date has passed. Step 3.
Check the front of the carton to make sure it is sealed ( Figure C ) . Do not use if the seal has been broken. If the expiration date has passed or the seal is broken, do not use.
Then go to Step 21 "Disposing of ENSPRYNG" and contact your healthcare provider. Figure C Step 4. Open the sealed carton (See Figure D ) .
Figure D Step 5. Carefully lift the syringe out of the carton by holding the barrel (See Figure E ) . Do not turn the carton upside down to remove the syringe.
Do not touch the activation guards because this may damage the syringe. Do not hold the plunger or needle cap. Figure E Check the syringe (See Figure F ) Step 6.
Check the expiration date on the syringe. Do not use the syringe if it has expired. Step 7.
Check the syringe for any damage. Do not use if it is cracked or broken. Step 8.
Check that the liquid through the viewing window is clear and colorless to slightly yellow. Do not inject the medicine if the liquid is cloudy, discolored, or has particles in it. There may be some small air bubbles in the syringe.
This is normal and you should not try to remove them. Figure F If the expiration (EXP) date has passed, the syringe… [Excerpted — this section continues on DailyMed.]
📄 Recent Major Changes ▾
Indication and Usage ( 1.2 ) 10/2026 Dosage and Administration ( 2.2 ) 10/2026 Dosage and Administration ( 2.3 ) 6/2026
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL - 120 mg/mL Syringe Carton NDC 50242-007-01 Rx only Enspryng ® (satralizumab-mwge) Injection 120 mg/mL For Subcutaneous Use. Single-Dose Prefilled Syringe. Refrigerate at 2°C to 8°C (36°F to 46°F) in original carton to protect from light.
Do not freeze. Do not shake. ATTENTION PHARMACIST: Each patient is required to receive the enclosed Medication Guide.
1 prefilled syringe Genentech 10240933 PRINCIPAL DISPLAY PANEL - 120 mg/mL Syringe Carton
PRINCIPAL DISPLAY PANEL - 120 mg/mL Autoinjector Carton NDC 50242-007-55 Enspryng ® (satralizumab-mwge) Injection 120 mg/mL For Subcutaneous Use. ATTENTION PHARMACIST: Each patient is required to receive the enclosed Medication Guide. Rx only 1 Single-Dose Autoinjector. Discard after use. Genentech 11034843 PRINCIPAL DISPLAY PANEL - 120 mg/mL Autoinjector Carton
PRINCIPAL DISPLAY PANEL - 180 mg/1.5 mL Autoinjector Carton NDC 50242-005-01 Enspryng ® (satralizumab-mwge) Injection 180 mg/1.5 mL For Subcutaneous Use. ATTENTION PHARMACIST: Each patient is required to receive the enclosed Medication Guide. 1 Single-Dose Autoinjector. Discard after use. R x only Genentech 11044874 PRINCIPAL DISPLAY PANEL - 180 mg/1.5 mL Autoinjector Carton
Medicare Part D spend CMS · PART D · 2026 (Q1)
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |